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http://www.trialsjournal.com/content/15/1/346RESEARCH Open AccessMeta-analysis of randomized phase II trials to
inform subsequent phase III decisions
Danielle L Burke1*, Lucinda J Billingham1,2, Alan J Girling1 and Richard D Riley3Abstract
Background: If multiple Phase II randomized trials exist then meta-analysis is favorable to increase statistical power
and summarize the existing evidence about an intervention's effect in order to help inform Phase III decisions. We
consider some statistical issues for meta-analysis of Phase II trials for this purpose, as motivated by a real example
involving nine Phase II trials of bolus thrombolytic therapy in acute myocardial infarction with binary outcomes.
Methods: We propose that a Bayesian random effects logistic regression model is most suitable as it models the
binomial distribution of the data, helps avoid continuity corrections, accounts for between-trial heterogeneity, and
incorporates parameter uncertainty when making inferences. The model also allows predictions that inform Phase
III decisions, and we show how to derive: (i) the probability that the intervention will be truly beneficial in a new
trial, and (ii) the probability that, in a new trial with a given sample size, the 95% credible interval for the odds ratio
will be entirely in favor of the intervention. As Phase II trials are potentially optimistic due to bias in design and
reporting, we also discuss how skeptical prior distributions can reduce this optimism to make more realistic predictions.
Results: In the example, the model identifies heterogeneity in intervention effect missed by an I-squared of 0%.
Prediction intervals accounting for this heterogeneity are shown to support subsequent Phase III trials. The probability
of success in Phase III trials increases as the sample size increases, up to 0.82 for intracranial hemorrhage and 0.79
for reinfarction outcomes.
Conclusions: The choice of meta-analysis methods can influence the decision about whether a trial should
proceed to Phase III and thus need to be clearly documented and investigated whenever a Phase II meta-analysis
is performed.
Keywords: Meta-analysis, Phase II and III, Prediction, Heterogeneity, BayesianBackground
Phase III trials are rigorous evaluations of an interven-
tion (such as a new drug or surgical technique), and are
typically protocol-driven with large patient numbers, ap-
propriate statistical power, and a suitable trial design and
analysis plan. However, the decision to initiate a Phase III
trial for a particular intervention is not straightforward
and depends on many factors, such as costs, risks (to the
trial funders and patients), and practicalities such as pa-
tient recruitment [1]. Perhaps the most pivotal factor is
the intervention's likely effectiveness. Clearly, the more
likely an intervention is to succeed, the more likely* Correspondence: d.burke@bham.ac.uk
1Medical Research Council Midland Hub for Trials Methodology Research,
School of Health and Population Sciences, University of Birmingham,
Edgbaston, Birmingham B15 2TT, UK
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© 2014 Burke et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
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unless otherwise stated.funders will risk investment in a Phase III trial. To this
end, before initiation of a Phase III trial funders will con-
sider the existing evidence about an intervention's poten-
tial benefit, for example from earlier Phase trials.
The initial estimate of the intervention effect often
arises from a Phase II randomized trial. These typically
contain small patient numbers or events, and give an
imprecise intervention effect estimate with a wide 95%
confidence interval. However, sometimes multiple Phase
II trials are conducted, for example in slightly different
patient groups or by different (or competing) researchers
(or companies) working on the same or similar interven-
tions. In this situation, a meta-analysis is useful to in-
crease statistical power [2] by combining the statistical
estimates (such as odds ratios (ORs)) from the multiple
trials and thereby summarizing the intervention effecttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that a meta-analysis of Phase III randomized trials is influ-
ential towards deciding whether a particular intervention
is used in clinical practice. However, there has been little
consideration of methods for meta-analysis of Phase II tri-
als, and how this approach might inform whether a Phase
III trial should be initiated.
In this article we describe the key statistical issues
when performing a meta-analysis of Phase II randomized
trials, as motivated by a real example in acute myocar-
dial infarction [4]. We show how Phase II meta-analysis
results can be used to predict the potential intervention
effect in a subsequent Phase III trial [5], and we explain
why such predictions might be misleading unless between-
trial heterogeneity and its estimation uncertainty are ac-
knowledged. As Phase II trial results are particularly prone
to optimism in the intervention effect, we also consider
how to incorporate realistic or skeptical clinical beliefs
about the size of the intervention effect [6]. The sensitivity
of the meta-analysis estimates and inferences to the choice
of prior distribution for the between-trial variance param-
eter is also explored [7]. We draw on previous discussions
about the interpretation of meta-analysis [5,8], more ap-
propriate modelling of binomial data in meta-analysis [9],
the derivation of prediction intervals for intervention ef-
fects in new trials [5], and the need to consider new tri-
als in the context of previous meta-analyses [10]. We
begin by outlining a motivating example of Phase II trials
of thrombolytic therapy, and then introduce key statistical
methods and issues with application to the example. We
then consider an extension to deal with potential opti-
mism and bias, and conclude with some discussion.
Methods
In this section we introduce a motivating example, and
then describe statistical methods for meta-analysis of
Phase II trials.
Motivating example: Phase II trials of bolus thrombolytic
therapy for acute myocardial infarction
In patients with acute myocardial infarction, thrombo-
lytic therapy aims to reduce mortality and restore nor-
mal blood flow by dissolving clots in blood vessels [11].
Eikelboom et al. [4] conducted a fixed-effect meta-analysis
of nine Phase II trials (Table 1) that evaluated the efficacy
of bolus thrombolytic therapy versus standard infusion
therapy for the in-hospital treatment of acute myocardial
infarction [11-19]. Two binary adverse event outcomes of
interest were reinfarction and intracranial hemorrhage
(ICH). Reinfarction is the clinical term given to a recur-
rence of a myocardial infarction (MI) that occurs within
28 days of an incident of a MI [20]. ICH is the accu-
mulation of blood within the cranial vault and can lead
to neurological dysfunction, elevation of intracranialpressure, and death [21]. For each outcome, Eikelboom
et al. [4] compare their meta-analysis of these Phase II
trials with a separate meta-analysis of six subsequent
Phase III trials [22-27] (Table 1) to study if, in retro-
spect, they were in agreement.
The forest plots summarizing the OR estimate and
95% confidence interval for each included trial and the
overall meta-analysis results are shown in Figure 1 for
ICH and Figure 2 for reinfarction. The summary ORs
obtained by Eikelboom et al. [4] appear similar for the
Phase II and Phase III meta-analyses for reinfarction.
However, for ICH the summary ORs are in opposite di-
rections for the Phase II trials (OR: 0.55 with 95% CI
0.29 to 1.06) and Phase III trials (OR: 1.25 with 95% CI
1.06 to 1.49). Therefore, it might appear that the Phase
II trials were a poor indication of how the intervention
would perform in subsequent Phase III trials. Eikelboom
et al. [4] suggest the discrepancy may be due to differ-
ences in patient populations and therapy intensity, along-
side potential design and reporting biases in the Phase II
trials.
In this article we evaluate this apparent conflict further
by considering more robust meta-analysis methods that
model the binomial distribution of the data, allow for
potential between-study heterogeneity in treatment ef-
fect, and better account for parameter uncertainty. We
show that, despite the visual discrepancy in the Phase II
and III summary results, the Phase III trial results for
ICH are entirely plausible given full consideration of un-
certainty, heterogeneity, and the correct interpretation
of a summary meta-analysis result.
Statistical methods for meta-analysis of Phase II trials
We now suggest methods for meta-analysis of Phase II
trials with binary outcomes, and consider issues such as
between-trial heterogeneity, zero cells, correct interpret-
ation of summary results, and predicting intervention ef-
fects in a subsequent Phase III trial.
A Bayesian meta-analysis model that accounts for
heterogeneity and uncertainty
The fixed-effect approach, as applied by Eikelboom et al.
[4] to the MI Phase II trials, assumes that all trials are
estimating the same common (fixed) intervention effect.
In other words, there is no between-trial heterogeneity
in the intervention effect and it is only due to chance
(sampling error) that the observed trial estimates vary. A
general fixed-effect meta-analysis model can be written
as follows (Model 1):
Y ieN θ;Var Y ið Þð Þ ð1Þ
Here, Yi is the intervention effect normal estimate (for
example the log OR) in trial i and Var(Yi) is its variance,
Table 1 Phase II and Phase III randomized trials of bolus versus infusion thrombolytic therapy for acute myocardial
infarction
Trial name, year published Length of follow-up Outcome Sample size, N Number of events (%)
Bolus Infusion Bolus Infusion
Phase II trials
RAPID [11] 1995 30 days ICH 452 154 1 (0.2) 4 (2.6)
Reinfarction 20 (4.4) 7 (4.5)
RAPID-II [12] 1996 35 days ICH 169 155 2 (1.2) 3 (1.9)
Reinfarction 8 (4.7) 7 (4.5)
Kawai et al. [13] 1997 7 days ICH 97 102 0 (0) 1 (1.0)
Reinfarction 4 (4.1) 7 (6.9)
Vanderschueren et al. [14] 1997 Hospital stay ICH 50 52 0 (0) 0 (0)
Reinfarction 5 (10.0) 7 (13.4)
BASE [15] 1998 Hospital stay ICH 139 53 2 (1.4) 0 (0)
Reinfarction 9 (6.5) 1 (1.9)
DOUBLE [16] 1998 30 days ICH 224 237 2 (0.9) 1 (0.4)
Reinfarction 5 (2.2) 12 (5.1)
lnTIME [17] 1998 30 days ICH 478 124 0 (0) 1 (0.8)
Reinfarction 9 (1.9) 8 (6.5)
TIMI 10B [18] 1998 30 days ICH 540 316 9 (1.7) 6 (1.9)
Reinfarction 28 (5.2) 18 (5.7)
TIMIKO [19] 1998 30 days ICH 350 268 1 (0.3) 3 (1.1)
Reinfarction 11 (3.1) 9 (3.4)
Phase III trials
INJECT [22] 1995 35 days ICH 2992 2994 23 (0.8) 11 (0.4)
Reinfarction 150 (5.0) 162 (5.4)
COBALT [23] 1997 30 days ICH 3585 3584 40 (1.1) 29 (0.8)
Reinfarction 140 (3.9) 147 (4.1)
GUSTO III [24] 1997 30 days ICH 10138 4921 92 (0.9) 43 (0.9)
Reinfarction 426 (8.7) 207 (2.0)
BIRD [26] 1998 30 days ICH 1196 1212 9 (0.8) 9 (0.7)
Reinfarction - -
ASSENT-2 [25] 1999 30 days ICH 8461 8488 79 (0.9) 80 (0.9)
Reinfarction 347 (4.1) 325 (3.8)
lnTIME-II [27] 1999 30 days ICH 10051 5027 114 (1.1) 31 (0.6)
Reinfarction - -
ICH, intracranial hemorrhage.
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only an estimate) [28]. The model can be estimated using
maximum likelihood, and the summary intervention effect
estimate ( θ^ ) will be a weighted average of the Yi values,
with trial weights equal to the inverse of Var(Yi).
There are important drawbacks of model 1, however,
in the context of a meta-analysis of Phase II trials.
Firstly, as the sample size (and number of events) in
each trial is likely to be small the assumption that Yi has
a normal sampling distribution may be inappropriate [9].Secondly, for each Phase II trial with no events in one of
the arms, an arbitrary continuity correction is required
in order to obtain Yi and its variance [29,30]. Thirdly,
and most importantly, the assumption of a fixed inter-
vention effect is unlikely to be realistic, especially if the
trials are undertaken in different places and populations,
conducted by different researchers (or companies), and
with varying lengths of follow-up and implementation
(e.g. dose). It is more plausible that the observed inter-
vention effect estimates will vary across trials due to
Figure 1 Meta-analysis of Phase II and Phase III trials for ICH. 'Original Overall' is the original summary results from the Phase II and Phase III
fixed effect meta-analyses reported by Eikelboom et al. [4]; 'Bayesian Overall' is the summary result from a Bayesian random-effects logistic regression
meta-analysis for the Phase II trials (see model 2), with 'tau' the estimated between-trial standard deviation. ICH, intracranial hemorrhage [11-19,22-27].
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in the intervention effect in each trial.
Therefore, an approach is needed to model the binomial
distribution of the data, avoid the need for continuity cor-
rections, and account for between-trial heterogeneity. Fur-
thermore, it is also desirable to account for uncertainty in
the estimation of between-trial heterogeneity. We there-
fore propose that a random-effects logistic regression
meta-analysis model is most suitable, within a Bayesian
framework [31]. For patient j (j = 1 to ni) in group xij (xij =
1 for treatment group, 0 for control group) of trial i (i = 1
to k), the model is (Model 2):
rijeBin 1;πij 
logit πij
  ¼ αi þ θixij
θieN θ; τ2 
Prior distributions:θeN 0; 10002 ; αieN 0; 10002 ; τeN 0; 1ð ÞI 0;ð Þ ð2Þ
In model 2, the event outcome status of patient j in
trial i is denoted by rij, which is 1 if the patient had the
event and zero otherwise; θi is the true treatment effect
(loge OR) in trial i, and the θi are assumed drawn from a
normal distribution with mean θ and between-trial vari-
ance τ2. The model accounts for the clustering of pa-
tients within trials by a separate intercept term, αi,
which denotes the baseline (control group) risk for each
trial [32]. In model 2, prior distributions must be speci-
fied for the unknown parameters (θ, αi and τ), which
allow other evidence (from outside the trials in the
meta-analysis) to be included if available and desired.
However, there is often no prior information regarding
these unknown parameters, and vague prior distribu-
tions are then necessary, such as those shown, with nor-
mal prior distributions with large variance given for θ
and αi. The prior distribution for τ is given as N(0,1)I
(0,), where I(0,) indicates the distribution is truncated at
Figure 2 Meta-analysis of Phase II and Phase III trials for reinfarction. 'Original Overall' is the original summary results from the Phase II
and Phase III fixed-effect meta-analyses by Eikelboom et al. [4]; 'Bayesian Overall' is the summary result from the Bayesian random-effects logistic
regression meta-analysis for the Phase II trials (see model 2), with 'tau' the between-trial standard deviation. The data for reinfarction was not
available for two of the six Phase III trials [11-19,22-25].
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for example, it could be made flatter and larger values
given more plausibility. However, previous authors have
identified that issues arise when the prior distributions
for variance parameters are unfeasibly wide [7], and there-
fore the N(0,1)I(0,) prior distribution is chosen to reflect a
realistic range of plausible values for τ for the MI example.
The impact of the choice of prior distributions for τ, θ,
and αi can be investigated, which is an important consid-
eration in any Bayesian analysis. This is considered further
in the Results section.
Posterior estimates of the parameters in model 2 can
be obtained using the Gibbs Sampler Markov chain Monte
Carlo (MCMC) method [33], which is implemented in
WinBUGS version 1.4, Medical Research Council Biostat-
istics Unit, Cambridge, UK [34] (WinBUGS code is avail-
able in Additional file 1: Supporting Information S1). In
this article, our model 2 analyses were performed with
100,000 iterations after allowing for a 100,000 iteration
burn in, and the samples were thinned by 10 to reduceany concerns of auto-correlation. The convergence of pa-
rameters was checked using history and trace plots. The
burn in and iteration length were chosen in advance to be
large to ensure that the estimation procedure had con-
verged and that the samples fully reflected the posterior
distributions, since in the example the trials had small
sample sizes and thus wide posterior distributions were
expected.
This estimation process enables one to summarize the
posterior distribution for the mean intervention effect
(θ) whilst accounting for the observed binomial data, the
posterior distribution of the between-study variance (τ2),
and the prior distributions for θ and τ. In particular, the
mean, median, and 95% credibility intervals can be de-
rived for the mean intervention effect.
Identifying heterogeneity in Phase II trials: misleading I2
To examine heterogeneity, researchers often use the I2
statistic, which measures the percentage of variability in
intervention effect estimates that is due to between-trial
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In the MI example, I2 is 0% in Phase II meta-analysis for
the ICH outcome, and many researchers might therefore
conclude that there is no heterogeneity in intervention
effects and use a fixed-effect model. However, as Phase
II trials are small (for example in terms of outcome
events) the variation due to sampling error will be ex-
tremely large relative to variation due to between-trial
heterogeneity. Thus, regardless of the magnitude of
between-trial heterogeneity, the uncertainty due to sam-
pling error will often dominate. Therefore, an I2 of 0%
(or close to 0%) is potentially misleading, as it may just
reflect the trials in the meta-analysis being imprecise.
This issue was raised by Higgins and Thompson [35]
when they introduced I2, and is highlighted in extensive
detail by Rucker et al. [36].
To address this, we agree with Rucker et al. [36] that
it is better to evaluate heterogeneity by focusing on the
estimate of the between-trial variance (τ2). Non-zero es-
timates suggest that heterogeneity is present. However, τ
will usually be estimated with large uncertainty, and so it
may be best to make an a priori decision regarding
whether to adopt a fixed-effect or random-effects model.
As the ultimate aim of a Phase II meta-analysis is to in-
form a potential Phase III trial, we consider it highly
preferable to adopt the random-effects approach by de-
fault. As mentioned, this more realistically allows for
heterogeneity in intervention effects, and accounting for
heterogeneity is an important factor when predicting po-
tential intervention effects in subsequent Phase III trials
(see Section “Using Phase II meta-analysis results to in-
form Phase III decisions”).
Dealing with double zero cells
As discussed, general meta-analysis methods such as
model 1 require a continuity correction if there are
treatment groups within trials with no events. Using the
binomial likelihood within model 2 alleviates this prob-
lem for trials where one group has a zero cell [9,37].
However, with small patient numbers and short follow-
up times, Phase II trials may occasionally provide zero
events in both treatment groups. In our example, this
causes estimation problems for model 2 during the
Gibbs sampling estimation of the posterior distributions.
To address this, the simplest solution is to exclude any
trial with a double zero cell. However we do not advo-
cate this because Phase II trials in the meta-analysis will
usually be small, and so even studies with a double zero
cell may contribute importantly toward the meta-analysis.
Furthermore, they contain valuable information from pa-
tients who consented to being included in the trial, and
ethically one should ensure their data are included. There-
fore, to include trials with double zero cells we applied a
continuity correction to them, which thereby avoids thecomputational issues in WinBUGS. We used the ‘treat-
ment arm’ continuity correction by Sweeting et al. [29],
which adds 1/(sample size of the opposite treatment
group) to each cell in a trial's two by two table, and per-
forms better than the standard approach of adding 0.5, es-
pecially when there are imbalances in the sample sizes in
each treatment group.
Using Phase II meta-analysis results to inform Phase III
decisions
Correct interpretation of summary meta-analysis result
When using the results from a random-effects meta-
analysis of Phase II trials to inform Phase III decisions, it
is crucial to interpret correctly the summary meta-analysis
result (θ^) as the estimate of the average intervention effect
from the whole distribution of possible effects [5,8]. The
posterior distribution for θ therefore reveals the most
likely values of, and the uncertainty of, this average inter-
vention effect.
Predicting the true intervention effect in a new Phase III
trial
When considering whether to conduct a Phase III trial,
focusing on the posterior distribution for θ may be mis-
leading when heterogeneity in present. The effect in a
new trial (θi) may be very different to the average effect
(θ), due to the causes of heterogeneity from trial to trial
(or setting to setting) [8]. Ideally, the factors causing the
heterogeneity would be known so that new trials could
focus on implementation strategies (for example doses)
and populations most likely to show benefit. However,
identifying causes of heterogeneity is problematic if there
are few studies (for example fewer than 10) in a meta-
analysis and the potential for trial-level confounding.
Therefore, we focus here on situations where the Phase
II trials in the meta-analysis all include pertinent places,
populations, and strategies (such as doses, timing, or
length of treatment) for which the intervention effect is
of interest.
In this situation, to inform the decision to proceed to
Phase III following meta-analysis model 2, one should
focus on the predictive distribution for θinew , the inter-
vention effect (log OR) in a new trial that is similar to
those already in the meta-analysis:
θineweN θ; τ2  ð3Þ
A 95% probability (credibility) interval for θinew can be
obtained by taking the 2.5% and 97.5% values of this dis-
tribution. This 95% interval has been referred to as a
95% prediction interval [5,8], and can be obtained imme-
diately after fitting model 2. As model 2 is a Bayesian
framework, the 95% interval will account for the uncer-
tainty in θ and τ2 through samples from their posterior
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tion for θinew to calculate the probability that the inter-
vention will be truly effective in the new trial [38], either
at all (probability(new OR <1)) or by some clinically
relevant amount, such as the odds being reduced by at
least 10% (probability(new OR <0.9)).
Predicting the chance of success in a Phase III trial with a
given sample size
Though the true intervention effect (θinew ) is of funda-
mental interest, a more pertinent question facing Phase
III funders is: what is the probability that the interven-
tion will be identified as beneficial in a new trial with a
given sample size? To help answer this, during the esti-
mation of model 2 one can also derive an approximate
predictive distribution for the intervention effect esti-
mate, Y inew , in a new trial of particular sample size, Ninew :
Y ineweN θinew ; var Y inewð Þð Þ ð4Þ
where θinew is the intervention effect in a new trial. The
variance of Y inew must be specified by the user, as it ac-
counts for the additional uncertainty that arises from the
sampling error in the new trial of a particular sample
size and event risk. In this article, to specify the variance
we utilise the well-known approximate formula for the
variance of:
1
ainew
þ 1
binew
þ 1
cinew
þ 1
dinew
ð5Þ
where ainew and cinew are the number of events in the new
trial’s experimental groups and control groups, respect-
ively, binew and dinew are the number of non-events in the
new trial’s experimental and control groups, respect-
ively, and the total sample size is Ninew ¼ ainew þ binewþ
cinew þ dinew . This calculation of the variance mimics how
it will be obtained when a new trial is done, as the for-
mula is based on the frequentist estimation, which is the
standard approach to analyze Phase III trials. At each it-
eration of the model estimation, the values of ainew ; binew ;
cinew and dinew are thus needed in order to derive the vari-
ance for each Y inew sampled during the estimation
process. We consider two options to achieve this here.
Option 1 is to fix the baseline risk (binew and dinew ) and
sample size in each group, which allows ainew andbinew to
be obtained for each Y inew sampled, and thus the vari-
ance of Y inew is then known. Option 2 is to assume a
fixed variance of Y inew regardless of the actual value of
Y inew sampling, again based on assuming particular sam-
ple sizes and event risks in both groups. The full details
of these options are provided in Additional file 1: Sup-
porting Information S2.Implementing options 1 or 2 allow for an approximate
95% probability interval for θinew to be calculated every
time Y inew is sampled, by:
Y inew  ð1:96 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
ainew þ 1 binew þ 1 cinew þ 1 dinew
 q
ð6Þ
Therefore, across all samples during the estimation
process, one can also derive predictive distributions for
the lower and upper bounds of the 95% interval for Y inew .
One can then calculate probabilities to inform Phase III
decisions. In particular the probability that, in a new
trial with a sample size of Ninew and a control group risk
of cinewcinewþdinew , the upper bound of the 95% interval for Y inew
will be lower than 0 (that the lower bound of the CI for
the OR will be <1). In other words, the probability that
the new trial will identify the intervention as effective
by the entire 95% interval for the OR being in favor of
the intervention.
Results
Application to the bolus thrombolytic therapy trials
We now consider the aforementioned statistical methods
and issues in relation to the thrombolytic therapy trials
introduced in the Methods section.
Misleading I-squared
I2 is 0 and 8% for the ICH and reinfarction outcomes,
respectively. Therefore, it might appear that there is very
little between-trial heterogeneity in the effect of bolus
therapy for both outcomes. However, after fitting the
Bayesian random-effects logistic regression in model 2,
the posterior distribution for τ has a median value of
0.66 and a 95% credible interval of 0.04 to 1.91 for ICH.
Similarly, for reinfarction, the median estimate for τ is
0.28 and has a 95% credible interval of 0.01 to 0.93. This
suggests that τ is not zero for either outcomes and thus,
in contrast to the initial conclusion from I2, heterogen-
eity does seem to exist and may even be substantial. This
highlights how I2 can be misleading when the included
trials are small [36].
Fixed-effect versus random effects results
As mentioned, application of model 2 to the data han-
dles all studies that had one zero cell, but required the
continuity correction of Sweeting et al. [29] in the study
containing a zero in two cells. The meta-analysis results
are shown in Table 2. The impact of this double zero
study on the meta-analysis conclusion was negligible;
compared to an analysis that excluded the study, the
means and medians of all posterior distributions were
very similar and standard deviations were only reduced
at the third decimal place.
Table 2 Meta-analysis results for ICH and reinfarction from a Bayesian model and the original frequentist approach
Outcome Summary OR 95% CrI/CI
for summary OR
τ^ (95% CrI) Probability
summary OR <1
Probability true
OR <1 in new trial
ICH
Bayesian 0.485 0.155 – 1.266 0.660 (0.043 – 1.914) 0.937 0.824
Original 0.552 0.287 – 1.063 - - -
Reinfarction
Bayesian 0.773 0.502 – 1.179 0.276 (0.013 – 0.929) 0.901 0.787
Original 0.779 0.568 – 1.066 - -
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from a Bayesian random-effects logistic regression model
(model 2) and from the original frequentist fixed-effect
approach of Eikelboom et al. [4]. CI, confidence interval;
ICH, intracranial hemorrhage; OR, odd ratio; CrI credible
interval.
The frequentist fixed-effect analysis results of Eikelboom
et al. [4] are compared to the Bayesian random-effects
model 2 results in Figure 1 and Figure 2, for outcomes
ICH and reinfarction respectively. For both approaches,
the summary ORs are in favor of bolus therapy (summary
OR <1). However, the fixed-effect meta-analysis gives 95%
confidence intervals that are much narrower than the 95%
credible intervals from the random-effects model, as the
latter more appropriately accounts for heterogeneity and
parameter uncertainty. For example, for ICH the 95% con-
fidence interval for the summary OR is 0.29 to 1.06 from
the fixed-effect analysis, and the 95% credible interval is
0.16 to 1.27 from the random-effects analysis. The 95%
credible intervals are wide, reflecting large uncertainty in
the summary intervention effect from the random-effects
analysis. This is unsurprising given the Phase II trials be-
ing synthesized have small sample sizes and heterogeneity
in the intervention effect estimate. However, the majority
of the intervals are below 1 (in favor of bolus therapy).Inferences for the predicted true intervention effect in a
new Phase III trial
Following model 2, the 95% prediction interval for the
true OR in a new trial can be calculated from the pre-
dictive distribution for θinew (Equation 3). For ICH, this is
calculated to be 0.05 to 3.79 (Figure 3), and for reinfarc-
tion this is calculated to be 0.29 to 2.04. These prediction
intervals are both much wider than the 95% credible inter-
vals for the summary (average) intervention effects for each
outcome, as they reveal the wider range of intervention ef-
fects across settings and populations due to heterogeneity.
Crucially these intervals overlap an OR of 1, and therefore
in some settings we cannot rule out that bolus therapy may
not be effective. However, the majority of the prediction in-
tervals are below 1. This can be quantified more formallyby calculating the proportion of the predictive distributions
for θinew that is below 0 (OR <1). This gives the probability
that bolus therapy will be more effective than control in a
new trial, and is 0.824 for ICH and 0.787 for reinfarction.
These reasonably large probabilities suggest that the ther-
apy has potential clinical value and that Phase III trials are
worth considering.Probability of success in a new trial with a given sample
size
Given that bolus therapy has large probability of being
truly effective in a new trial, funders next need to consider
whether a Phase III trial is likely to show this statistically.
For simplicity, consider just ICH and let us calculate the
probability that, for a trial with a given sample size, the de-
rived 95% interval for the OR will have an upper bound
less than 1. We consider both options 1 and 2 for obtain-
ing the variance of Y inew to derive this interval.
Let us assume a control group risk of 0.01 for ICH in
the new trial (a plausible baseline risk from previous tri-
als [4]), which is the probability of an ICH event in the
infusion therapy group. Under this assumption, the
probability that bolus therapy will be shown to be effect-
ive in the new trial is illustrated in Figure 4, for varying
chosen sample sizes and for each of options 1 and 2. As
the sample size increases, the probability of success in a
new trial also increases, which reflects the narrower
credible intervals that arise from larger patient numbers.
Options 1 and 2 give reasonably similar results.
When the sample size is unrealistically large (10,000,000
patients per arm), such that the trial is tending toward
an infinite sample size, the probability of success tends
to the probability that exp(θinew ) is less than one, which
equals 0.824 as noted above. For more realistic sample
sizes, the probability of success is much lower. For ex-
ample, with 2,000 patients in each arm of the trial the
probability of success is only about 0.4. However, in-
creasing to 4,000 patients per arm increases the success
probability to about 0.6. In this manner, Figure 4 reveals
to funders how much is gained (in terms of success
probability) by increasing the sample size. They can
-3 -2 -1 0 1 2
Favours bolus Favours infusion
Original Phase II meta-analysis
Bayesian Phase II meta-analysis prediction interval
lnTIME-II
ASSENT-2
BIRD
GUSTO-III
COBALT
INJECT
ln(Odds ratio)
Intracranial haemorrhage
Figure 3 Comparison of Bayesian prediction interval from Phase II meta-analysis with original meta-analysis and subsequent Phase III
trials for ICH. lnTIME-II, ASSENT-2, BIRD, GUSTO-III, COBALT and INJECT are the six subsequent Phase III trials, which compared bolus to infusion
therapy for patients with an acute myocardial infarction. Horizontal lines indicate the 95% confidence intervals for the estimated log ORs in the
Phase III trials and the original Phase II meta-analysis, and the 95% prediction interval in the Bayesian Phase II meta-analysis [22-27].
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to recruit more individuals.
Comparison with subsequent randomized Phase III trials
As introduced in the Methods section, Eikelboom et al.
[4] conclude that the meta-analysis results are contra-
dictory for Phase II and subsequent Phase III trials for
ICH (Figure 1 and Table 2), as their summary results are0
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Figure 4 Probability that the upper bound of the OR's 95% credible i
(option 2) indicates the variance of Yinew is assumed to be a fixed value wh
group, a particular sample size, and a treatment effect of 0.485 (summary O
variance of Yinew is calculated for each sample of the estimation process, as
size, and using the sampled (θinew Þ (Equation 6).in opposite directions with very little overlap in their
confidence intervals; Phase II trials favor bolus therapy,
whereas Phase III trials favor infusion therapy. However,
their comparison was inappropriate, as their analysis ig-
nored heterogeneity in the treatment effect. Indeed, the
apparent disagreement in their Phase II and III summary
results is potentially resolved when considering the 95%
prediction interval for the OR in a new trial that can be6000 8000 10000
 group in new trial
Sampled variance (option(1))
nterval may be less than 1 in a new trial for ICH. Fixed variance
ich is approximated by assuming a baseline risk of 0.01 in the control
R estimate from model 2). Sampled variance (option 1) indicates the
suming a baseline risk of 0.01 in the control group, a particular sample
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above, this 95% prediction interval is 0.05 to 3.79 and is
wide due to the large heterogeneity and uncertainty
present. This interval includes all the estimates of treat-
ment effect for ICH obtained from the subsequent Phase
III trials (Figure 3), suggesting that Eikelboom et al. [4]
were incorrect as the Phase III results are plausible given
the Phase II evidence. It is conceivable that the settings
and populations of subsequent Phase III trials related
more to those effects towards the upper side of the 95%
prediction interval.Choice of prior distribution for between-trial variance
The choice of vague prior distribution for the between-
trial variance (τ2) in model 2 is not a trivial decision [7,39],
and may influence the posterior inferences. Table 3 shows
the summary estimates and 95% prediction intervals for
the OR for ICH in a new study, as obtained from model 2
and Equation 3 using a variety of different prior distribu-
tions. Figure 5 shows the posterior distributions for θinew
for priors 2 and 6 in Table 3. The summary treatment ef-
fect estimate is similar regardless of the prior chosen.
However, the width of the posterior distribution for the
treatment effect is vulnerable to the choice of prior, and
this affects the 95% prediction intervals. Where possible,
external evidence regarding the between-study heterogen-
eity may be useful to include within the prior distribution
to ensure vague but realistic prior distributions are chosen
as discussed [6].Adjusting for potential optimism in Phase II results
The estimates of the OR in the individual Phase III trials
for ICH and reinfarction are closer to one when com-
pared to most of those from the individual Phase II tri-
als. As shown, this is plausibly due to the heterogeneity.
However, as Eikelboom et al. [4] discuss, it may also be
due to optimism and bias in the Phase II trials. Indeed it
is common in medical research for interventions to
show early promise, only for subsequent large studies to
show no or lower benefit [40]. For this reason, following
a meta-analysis of Phase II trials, it may be important toTable 3 Sensitivity to prior distribution for between-trial vari
Prior distribution OR 95% prediction interva
1: τ ~ Uniform(0,2) 0.470 0.032 - 5.751
2: 1/τ2 ~ Gamma(0.1, 0.1) 0.465 0.021 - 7.938
3: Log(τ2) ~ Uniform(−10,1.386) 0.499 0.094 - 2.097
4: τ2 ~ Uniform(0.001,4) 0.449 0.020 - 8.652
5: 1/ τ2 ~ Pareto(1,0.25) 0.447 0.020 - 8.496
6: τ ~ Normal(0,1)I[0,] 0.485 0.049 - 3.793
ICH intracranial hemorrhage; OR odds ratio; CrI credible interval.account for potential optimism when predicting the
treatment effect in subsequent Phase III trials.
Examining potential publication bias
One cause for potential optimism may be publication bias,
which is an issue that occurs when trials with more favor-
able results are more likely to be published than those
with less favorable results [41]. Publication bias can be ex-
plored using funnel plots where, if there is no evidence of
publication bias, the assumption is that the trials should
be symmetrically distributed about the estimates from lar-
ger studies, in a funnel-like shape. A funnel plot of only
the Phase II trials for ICH in Figure 6 suggests that there
is no clear evidence of publication bias since the observed
estimates appear equally spread in both directions around
the estimates from the largest Phase II trials. This con-
tradicts the asymmetric funnel plot for ICH shown by
Eikelboom et al. [4] (Figure 6), which displayed both
Phase II and Phase III trials. This suggests asymmetry in
their plots may have been caused by heterogeneity ra-
ther than genuine publication bias [42]. The funnel plot
for reinfarction (not shown) in the Phase II trials also
shows no clear evidence of asymmetry.
Including skeptical prior distributions to adjust for
optimism
Assessment of potential publication bias is difficult, and
usually at least 10 studies are recommended [43]. Even if
there is no clear evidence of publication bias, Phase II
trials may be more prone to bias in their design, execu-
tion, and analysis, which could also cause optimistic
meta-analysis results for Phase II trials. It is possible to
limit the potential optimism in the Bayesian analysis by
using a realistic or ‘skeptical’ prior distribution for the
pooled intervention effect that does not allow large
intervention effect sizes [6,40]. Caution must be taken
when deriving a skeptical prior distribution as there is a
danger of using an informative prior not based on evi-
dence of plausibility. Therefore clinical guidance is
needed, or evidence from external trials can be used, to
inform a plausible magnitude of treatment effect. For ex-
ample, the external trial information could come from aance in prediction interval for treatment effect for ICH
l OR τ^ (95% CrI) Probability OR in new trial <1
0.915 (0.065 - 1.920) 0.788
0.825 (0.244 - 3.146) 0.787
0.139 (0.008 - 1.654) 0.907
1.257 (0.293 - 1.959) 0.741
1.260 (0.293 - 1.960) 0.742
0.657 (0.037 - 1.911) 0.824
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τ~N(0,1)I(0,) 1/τ2~Gamma(0.1,0.1)
Figure 5 Posterior distribution for treatment effect in a new trial (θinew Þ for intracranial hemorrhage assuming two different priors for
the heterogeneity parameter.
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http://www.trialsjournal.com/content/15/1/346trial where a similar treatment was evaluated (such as a
drug from the same class), but perhaps in a different dis-
ease area or patient group. Spiegelhalter et al. [6] discuss
how to mathematically derive a skeptical prior distribution
based on plausible treatment differences where there is only
a small probability that the treatment effect is as large as
the alternative hypothesis. For example, a skeptical prior
distribution on the summary OR could be such that there
is little chance (say just 5%) that the experimental treatment
would reduce the odds of the event of interest by more0
2
4
6
1/
SE
(lo
g(O
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)
.1 .485
OR
Phase II trials
Figure 6 Funnel plot of 1/SE(log(OR)) versus OR for ICH in Phase II an
effect estimate for ICH from the Bayesian random-effects logistic regression
summary treatment effect estimate for ICH by Eikelboom et al. [4] for the P
intracranial hemorrhage, SE standard error.than, say, 25% compared to the control treatment. This
could relate to the summary log OR having a prior Normal
distribution, with mean zero and variance 0.03. Figure 7
shows how this skeptical prior distribution for θ alters the
posterior distribution for the intervention effect (θinew ) in a
new trial for ICH, compared to the original vague prior
distribution for θ in model 2. The posterior distribution
is drawn closer to zero, and consequently, the probabil-
ity that the estimated OR is less than 1 in a new trial is
now lower. It should be noted that the use of skeptical1.25 10
 for ICH
Phase III trials
d Phase III trials. Dotted line represents the summary treatment
analysis (model 2) of the Phase II trials; dashed line indicates the
hase III trials. The OR axis is shown on the log-scale. OR odds ratio; ICH
AUC: Prob(decreased odds ICH)=0.82
AUC: Prob(decreased odds ICH)=0.59
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Figure 7 Posterior distributions for treatment effect (log(OR)) in a new trial for ICH assuming a skeptical and vague prior distribution
for log(OR). Vague prior distribution (θ ~ N(0,10002)) and skeptical prior distribution (θ ~ N(0,33.33)) for the log OR. The area under the curve
(AUC) that is less than zero is the probability that bolus therapy will truly be effective in a new trial. ICH intracranial hemorrhage; AUC area under
the curve.
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analyses of Phase II trials; it will depend on factors such
as the perceived quality (risk of bias) of the available
Phase II trials, and whether the meta-analysis results
otherwise appear optimistic relative to evidence of the
effectiveness of related interventions in the same or re-
lated disease area.
Discussion
The decision to progress to Phase III is based on all
existing evidence, which includes information other than
the results of Phase II trials, such as costs and feasibility.
However, if multiple Phase II trials exist, such as in the
example by Eikelboom et al. [4] in this paper and others
identified by the Cochrane Collaboration (such as [44]),
a meta-analysis of the Phase II trials should be consid-
ered important. The example in this paper has illustrated
that meta-analysis of Phase II trials can be useful to in-
form Phase III trial decisions. We have tackled a number
of methodological issues that arise when conducting a
meta-analysis of Phase II trials. In particular, the choice
of meta-analysis model, how to deal with heterogeneity
[5] and zero cells [29], and how to translate the meta-
analysis results to inform new studies. Sutton et al. [10]
have also considered the use of meta-analysis to inform
the sample size of future trials (but not in the context of
Phase II and III) and mainly in relation to how updated
meta-analysis results could change after the new trial is
performed.
Heterogeneity is a genuine problem in meta-analysis
and to ensure the Phase II meta-analysis is relevant toPhase III decisions, we recommend that heterogeneity is
reduced by only including those Phase II trials that are
relevant to the populations and settings for which the
intervention is intended. It is difficult to examine and
quantify the potential heterogeneity in a meta-analysis of
Phase II trials due to the small number of studies and
the small number of patients within studies, which can
cause low power and large within-study variation. The I2
statistic is always likely to be small when within-study
variances are large, as shown for the ICH outcome [36].
Since Phase II trials have small patient numbers and are
often conducted separately, we believe it is likely that
heterogeneity exists and so should be accounted for.
Therefore, researchers may decide a priori that a random-
effects model will be used for the meta-analysis, and
thereby avoid reliance on I2.
When informing Phase III decisions, we have shown
the importance of deriving prediction intervals for the
true intervention effect in a new trial [5] and, perhaps
most pertinently, the probability of observed success for
a new trial with a given sample size. These are more
meaningful than the summary meta-analysis result itself,
which relates only to the average effect [8]. The Bayesian
framework naturally incorporates heterogeneity and par-
ameter uncertainty, which means that posterior distribu-
tions for the intervention effect in a new trial reflect the
uncertainty in potential Phase III trial results. Bayesian
meta-analysis methods lead naturally to direct probabil-
ity statements, and can also limit potential bias and opti-
mism in the prediction intervals from Phase II trials
through skeptical prior distributions [6]. However, the
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ence the results [7,39] and therefore sensitivity to the
choice of prior distribution is recommended.
We envisage that, in most situations, a meta-analysis
of Phase II trials is likely to reveal the large uncertainty
upon which the Phase III trial decision is based, even
despite results of the individual trials being pooled. The
small sample sizes in Phase II trials, and the rare event
rate in these particular trials, combined with between-
trial heterogeneity in intervention effects, are the key
contributing factors to the large uncertainty. This makes
the posterior distribution (and 95% prediction intervals)
wide, but this is merely a full reflection of the informa-
tion available and will ensure funders are fully aware of
statistical uncertainty when making their decisions for
Phase III. Funders can improve their chances of a Phase
III success by increasing sample sizes (Figure 4), but this
causes an increase in trial costs. Other considerations
away from statistical uncertainty are also crucial of course,
such as the biological understanding of a drug's mechan-
ism, the acceptability of the intervention of interest, and
the market demand for the intervention. Therefore Phase
III predictions should be just one, albeit important, part of
the decision-making process.
Relevance of our work to recent meta-analyses of Phase II
trials
In this paper, we focused on improving the meta-analysis
of Phase II trials conducted by Eikelboom et al. [4], in
which they ignored heterogeneity by using a fixed-effect
model, and did not model directly the binomial distribu-
tion of the data. We also identified other examples, in
more recent years, where the method for meta-analyzing
Phase II studies could be improved similarly. In particular,
the decision to use a fixed-effect or random-effects model
is often based on the P value derived from the Q statistic
(chi-squared test for heterogeneity [3]) and/or the I2 stat-
istic [45-48]. If the P value from the chi-squared test is
not statistically significant, and/or I2 is low, a fixed-effect
model is often used. However, with few studies there isTable 4 Recommendations for improved meta-analysis of Pha
Issue Recommendation
Framework Use a logistic regression model to
data within studies, and to avoid c
Choice of model Do not make decisions to use a fix
Heterogeneity State a priori that a random-effects
Uncertainty Use a Bayesian framework to accou
evidence (such as the between-stu
However, a sensitivity analysis to th
Prediction intervals Report 95% prediction intervals as
and inform subsequent Phase III de
Bias Use skeptical prior distributions for
Phase II trials may be biased in favvery low power to detect heterogeneity, and therefore a
significant P value is unlikely in the meta-analysis of Phase
II trials and so genuine heterogeneity may be ignored.
Similarly, we showed low values of I2 are also potentially
misleading for Phase II meta-analysis.
We are aware of two meta-analyses of Phase II trials
where authors decided a priori that a random-effects
model was more appropriate because of the expectation
that the studies would estimate different, yet related, treat-
ment effects [44,49]. This approach concurs with our rec-
ommendation above. However, in these and other articles
using a random-effects model, the conclusions only fo-
cused on the pooled estimate of the average treatment ef-
fect, and the prediction interval for the treatment effect in
a new trial was not considered [44-49]. Thus, the full un-
certainty of the potential treatment effect in new popula-
tions (or Phase III studies) is often ignored. Finally, it is
also common for meta-analyses of Phase II trials to pool
treatment effects using the inverse variance method
(model 1), rather than modelling the binomial distribution
of the data more exactly as shown in model 2 [44-49].Conclusions
The choice of meta-analysis methods can influence the
decision about whether to proceed to Phase III and thus
the methods need to be clearly documented and investi-
gated whenever a Phase II meta-analysis is performed.
Eikelboom et al. [4] originally conducted a fixed-effect
meta-analysis of Phase II trials and compared the results
to a meta-analysis of subsequent Phase III trials. They
concluded that there were conflicting results between
the two meta-analyses for ICH. However, our Bayesian
random-effects logistic regression analysis with esti-
mated prediction intervals shows that the results are not
necessarily contradictory.Recommendations for good practice
Table 4 summarizes our recommendations for good
practice within meta-analysis of Phase II trials.se II trials of binary outcomes
model the binomial distribution of the
ontinuity corrections given a zero event in one arm.
ed-effect or random-effects model based on I2 or tests for heterogeneity.
model will be used to account for heterogeneity in treatment effects.
nt for all parameter uncertainty and external
dy variance) and to enable direct probabilistic inferences.
e choice of prior distributions is required.
they reveal the potential treatment effect in a new population,
cisions.
the treatment effect if there is evidence to suggest the
or of the treatment.
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